U.S. pharma big copyright scrapped two experimental weight loss drugs last year—a after-each day tablet, lotiglipron, because of elevated liver enzymes and a twice-day by day tablet, danuglipron, resulting from sturdy side effects—but CEO Albert Bourla has reported the company is determined to “Participate in and get” from the being overwei